Back to search

University of Strathclyde

Iridium-catalysed hydrogen isotope exchange of pharmaceutically-relevant sulfoximines and selective fragment coupling of two unactivated alcohols

Abstract

dc:description.abstract

Chapter 1Deuterium- and tritium-labelled pharmaceutical candidates have become invaluable for invivo and in vitro studies conducted in both a preclinical and clinical context. The preparationof these deuterium, or tritium, containing molecular architectures has been largely enabledby transition metal-catalysed hydrogen isotope exchange.Within this field, work in our laboratory has led to the design of a suite of iridium(I) Nheterocyclic carbene complexes tailored towards the late-stage functionalisation of C(sp2)–Hsites located within aromatic and heteroaromatic systems ortho to a Lewis basic directinggroup.Within this chapter, we describe the expansion of our ortho-directed labelling strategy to thesulfoximine functional group. Extending from this, a method for the straightforwardprediction of the outcome of the arene functionalisation process was developed. Moreover,we have uncovered a novel C–H activation pathway at challenging to label S-methyl C(sp3)–Hcentres. The generality of our catalytic systems is demonstrated through the successfuldelivery of isotopic substituents into high-complexity substrates.Chapter 2Metal-catalysed allylic substitution has emerged as a leading technology for the constructionof carbon–carbon and carbon–heteroatoms bonds at C(sp3)-centres of allylic electrophiles.However, within this arena highly substituted allylic frameworks are seldom used.In recognition of this, this section of this thesis describes development of a method to directlycouple unactivated highly substituted allylic electrophiles and alcohols, to form etherproducts. Through use of a catalyst design plan an optimal pre-catalyst was identified for aniridium-catalysed etherification protocol that operates under hydrogen activation. Following this, mechanistic understanding of this transformation was used to developanother etherification system which utilises an acid additive, in place of the hydrogenatmosphere. To accelerate the discovery and development of the acid additive system, a highthroughput screening approach was utilised to enable the rapid identification of promisingacid additives.PrefaceResearch within modern medicinal chemistry has been devoted to the generation anddiversification of novel frameworks in the pursuit of previously elusive molecular solutionsfor high value targets. Among these motifs, sulfoximines have risen to prominence within thepharmaceutical industry. We therefore envisioned that our range of iridium(I) carbene precatalysts could be programmed to permit access to an unprecedented collection ofisotopically-enriched pharmaceutically relevant free and N-functionalised sulfoximinearchitectures, through a synergistic experimentally and computationally guided approach.Through this approach existing pre-catalysts that our group have previously developed werecomputationally screened to identify an appropriate hydrogen isotope exchange catalyst forour targeted transformation. From this, an ortho-directed labelling strategy mediated via thesulfoximine functional group and a complementary system capable of labelling C(sp3)–Hcentres located at S-methyl position were established. Following completion of the first project focus was placed on showcasing the versatile natureof our iridium(I) pre-catalyst range through expansion of their use to other areas of transitionmetal catalysis. Accordingly, we targeted the direct functionalisation of highly substitutedunactivated allylic alcohols to provide access to a range of products substituted at C(sp3)-centres, given the statistical correlation between the degree of carbon saturation and thepresence of stereogenic centres featured in medicinal candidates with clinical success.More specifically, the establishment of a system that can directly couple allylic electrophilesand alcohols, to form ether products was pursued. To achieve this, we used a catalyst designplan to tune our pre-catalyst range to promote this allylic substitution type transformation,where we moved away from the electron rich variants of our pre-catalysts that are used inthe hydrogen isotope exchange of various molecules. Collectively, the second chapter of thisreport outlines the broadening of the utility of our laboratories iridium(I) pre-catalyst rangethrough the development of an iridium-catalysed fragment coupling protocol.

Degree

thesis:*
Name dc:type.qualificationname
phd
Level dc:type.qualificationlevel
doctoral-pg
Grantor dc:publisher.institution
University of Strathclyde
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Smith, Blair
Advisor dc:contributor.advisor
  • Kerr, William
Author Identifier dc:creator.authoridentifier
  • 202065419

Rights

Identifiers

dc:identifier.*
Identifier
T17217

Chain of custody

source
Harvested from
University of Strathclyde
Base URL
stax.strath.ac.uk/catalog/oai
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Smith, Blair. Iridium-catalysed hydrogen isotope exchange of pharmaceutically-relevant sulfoximines and selective fragment coupling of two unactivated alcohols. doctoral-pg thesis, University of Strathclyde, 2025. https://stax.strath.ac.uk/concern/theses/x633f1553